FOLFOXIRI vs FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E mutated primary tumor: phase III CAIRO5 study. Issue 2 (February 2023) - Bond, Marinde